CD45BE-HSPC + CART-45 Cells

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT07451054
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • B-Cell Non-Hodgkin Lymphoma (NHL)
  • Hodgkin Lymphoma
  • Richter's Transformation
  • T-Cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CART-45 cells — BIOLOGICAL
    Autologous base edited anti-CD45 CAR T cells
  • CD45BE-HSPC — BIOLOGICAL
    CD45 base edited hematopoietic stem and progenitor cells

Study Details

This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.

Key Dates

Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
Jul 31, 2051
Completion
Jul 31, 2051

Study Design

Enrollment
42 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A: B-cell Non-Hodgkin Lymphoma (B-cell NHL), Richter's Transformation (RT)
  • Experimental: Cohort B: T-cell Non-Hodgkin Lymphoma (T-cell NHL), Hodgkin Lymphoma (HL)

Primary Outcome Measure

Incidence of Adverse Events as assessed by CTCAE v6.0 [ Time Frame: Up to 15 years post infusion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of PennsylvaniaPhiladelphiaPennsylvania19104
Abramson Cancer Center Clinical Trials Service
[email protected]
215-349-8245

Find similar trials in Philadelphia, PA

By research site
University of Pennsylvania· Philadelphia, PA

Related Studies